Sugi Predict
/ Targets
/ FANCD2
Top predicted compounds (top 20 by supporting neighbours, then confidence)
| Compound | Confidence | Supporting neighbours |
|---|
Clinical trials — most relevant to FANCD2 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Niraparib and Dostarlimab in HRD Solid Tumors |
PHASE2 | UNKNOWN |
| Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors |
PHASE2 | COMPLETED |
| Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100 |
PHASE1/PHASE2 | COMPLETED |
| I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency |
PHASE2 | COMPLETED |
| Efficacy and Safety of PARPi to Treat Pancreatic Cancer |
PHASE2 | COMPLETED |
| Eltrombopag for People With Fanconi Anemia |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Olaparib in Treating Patients With Stage IV Pancreatic Cancer |
PHASE2 | COMPLETED |
| Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. |
PHASE2 | COMPLETED |
| Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| Gene Therapy for Fanconi Anemia, Complementation Group A |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI |
PHASE1/PHASE2 | RECRUITING |
| Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| M6620 (VX-970) in Selected Solid Tumors |
PHASE2 | COMPLETED |
| Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission |
PHASE1/PHASE2 | COMPLETED |
| HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy |
PHASE2 | RECRUITING |
| Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation |
PHASE2 | UNKNOWN |
| Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation |
PHASE2 | UNKNOWN |
| A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors |
PHASE1 | COMPLETED |
| Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer |
PHASE1 | ACTIVE_NOT_RECRUITING |
| Gene Therapy for the Treatment of Fanconi's Anemia Type C |
PHASE1 | COMPLETED |
| Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors |
PHASE1 | COMPLETED |
| Corrective Exercise and Rehabilitation in Fanconi Anemia: A Case Study |
nan | COMPLETED |
| Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma |
nan | COMPLETED |
| Microcephaly Genetic Deficiency in Neural Progenitors |
nan | COMPLETED |
| Clinical Genetics Branch Eligibility Screening Survey |
nan | NOT_YET_RECRUITING |
| Utility of a Urine Screening Tool for Vitamin D Deficiency in Infants and Toddlers |
nan | COMPLETED |
| Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base |
nan | RECRUITING |
| Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene Therapy |
nan | ACTIVE_NOT_RECRUITING |
Related proteins — ESM-2 sequence neighbours (a FANCD2 binder may also engage these)